🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This review on long-term toxicities from cancer therapy covering the “classic side effects” plus financial toxicity and psychosocial needs published in NatureRevClinOncol by Maryam Lustberg MD, MPH, FASCO Dr K., MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Aakash Desai, MD, MPH, FASCO Cristiane D Bergerot and Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 is a must read 👇 OncoAlert 🚨

Nothing to add here! OncoAlert 🚨

#MentalHealthMatters

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials out on Journal of Clinical Oncology Study investigates the impact of immunosuppressive treatment💊 on survival in patients with various tumor types receiving anti–PD-1 +

I am back after taking a break from #socialmedia. The exhaustion of working on an ICU & trying to keep an academic career going, caught up on me. I needed to breathe… I apologize to my amazing colleagues from the OncoAlert 🚨associate faculty whom I left unannounced 🫣

The OncoAlert 🚨 coverage of the last week is out, including a very interesting article on corticosteroids and checkpoint inhibitors!

Just Out on JAMA Oncology Patient Page: Caring for Your Heart❤️During Cancer Treatment by our #OncoAlertAF 🚨Colleague Eric K. Singhi, MD 🇺🇸and Team Manu Mysore, MD FACC Dylan Singhi Cardio-oncology is a specialized field that focuses on managing heart health in individuals undergoing #Cancer

Stay tuned! OncoAlert 🚨 has got you covered during #ESMO24!

#youngoncologists were killing it in the breast mini-orals session #ESMO24❗️❗️ Shoutout to all established investigators: give them the stage and they won’t disappoint! #Mentorship #ESMO4carers ESMO - Eur. Oncology Nadia Harbeck,MD PhD MarleenKokLab #ESMOAmbassadors

#ESMO24 ESMO - Eur. Oncology Presidential Session I🥇 #anal #cancer POD1UM-303/InterAACT2 - Dr. Sheela Rao 📌n=308, ph 3🌎1L advanced anal SCC carbo/taxolx6 +/- PD1-retifanlimab 1:1 (w/ crossover 35%) 📌 n=308, ~75%F, ~80%M1, 3% HIV+,90% PDL1+ ➡️mPFS 9.3 v 7.4m, HR 0.63, p=0.0006 (primary)

Having trouble staying on top of everything that is happening during #ESMO24? OncoAlert 🚨 has got you covered! You find the link to sign up for the newsletter below 👇

Great session for #YOC on #PrecisionMedicine during #ESMO24 with Ben Westphalen 🎯

Impact of primary tumor sidedness and sex on prognosis and anti-EGFR efficacy in BRAF-mutant mCRC ESMO Open doi.org/10.1016/j.esmo… 🔎 pooled analysis of FIRE-1, CIOX, FIRE-3, XELAVIRI, & VOLFI 👉Benefit in LSPT 👉Worse outcome in RSPT 🧐hypothesis-generating.... ESMO - Eur. Oncology

The path to power is still a maddening tightrope walk for women. We expect men to be strong & capable, but women to be warm & modest too. We mistake their assertiveness for selfishness and vulnerability for weakness. We should hold all leaders to common standards of competence

Dear Colleagues The OncoAlert🚨 Network along with our partners at European Society of Surgical Oncology (ESSO) ESGO MASCC & SIOG invite you to the #OncoAlertColloquium REGISTER for FREE HERE👉 buff.ly/3CChgre February 3-9, 2025 💯% Virtual & Interactive Watch Our #BreastCancer

The OncoAlert🚨Newsletter Now Out Covering March 14-20, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅🫁🔑❄️ ✅Fertility Preservation Guidelines ASCO 🤰 ✅ #LITESPARK in #KidneyCancer ✅ #KEYNOTE921 🔑 in #ProstateCancer ✅ #ADAURA 🫁 in

This is so important as we continue to see more younger patients in our daily practice!

And the fun starts! From @asco #asco25 press release Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. PFS pic below NEJM asco.org/about-asco/pre…

OUT NOW The OncoAlert🚨NEWSLETTER 🔥THE COMPLETE #ASCO25 EDITION 🇺🇸 REGISTER HERE buff.ly/48Xpgz0 OR OncoAlert360.com With GREAT VIDEO Insights from Authors courtesy of our Collaborators at VJ Oncology high5md & COR2ED ‼️

Missed #ASCO25? No problem! OncoAlert 🚨has got you covered! The amazing faculty around Gil Morgan, MD has put together a comprehensive overview of the entire congress! 👇